Barclays analyst Andrew Mok raised the firm’s price target on CVS Health (CVS) to $80 from $79 and keeps an Overweight rating on the shares following the Q2 report.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVS:
- CVS Health Reports Strong Q2 Revenue Growth Amid Challenges
- Unusually active option classes on open July 31st
- Morning Movers: Roblox skyrockets following second quarter results
- CVS Health says maintaining ‘prudent view’ on medical cost trends for full year
- CVS Health says confident in adequacy of reserves